Genentech announced that the FDA has accepted a new drug application and granted priority review for the company’s single-dose, oral influenza treatment baloxavir marboxil.
The investigational medication is designed to inhibit the cap-dependent endonuclease protein crucial for influenza virus replication, including in oseltamivir-resistant and avian strains, according to a news release. It is intended for patients aged 12 years and older with acute, uncomplicated influenza.
AKH Inc., Advancing Knowledge in Healthcare and Psychiatric Annals
American Academy of Pediatrics National Conference & Exhibition
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2018 Healio All Rights Reserved.